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Proteinuria predicting outcome in renal disease: Nondiabetic
nephropathies (REIN). About two thirds of patients on re-
nal replacement therapy irreversibly lose their kidney function
because of progressive nephropathies, such as diabetic
nephropathy and nondiabetic chronic renal disease. Halting
the progression of these patients to end-stage renal disease
(ESRD) is instrumental to substantially decrease the need and
cost for renal replacement therapy. A large number of experi-
mental studies have demonstrated that chronic nephropathies
share common pathogenic mechanisms that contribute to re-
nal disease progression, even independently of the original eti-
ology. Actually, a variety of insults may result in a common
pathway of systemic hypertension, increased glomerular pres-
sure and protein ultrafiltration, glomerular and tubular protein
overload, chronic inflammation and, ultimately, scarring. Ex-
perimental and clinical data converge to indicate that in chronic
renal disease increased protein traffic is nephrotoxic, protein-
uria predicts disease progression, and proteinuria reduction is
renoprotective. Initial clinical trials, mostly in patients with no
or mild proteinuria, failed to demonstrate that ACE inhibition
therapy is renoprotective in nondiabetic chronic nephropathies.
Consistently, meta-analyses based on data generated by these
trials failed to detect a specific, blood pressure–independent,
renoprotective effect of ACE inhibition therapy. The Ramipril
Efficacy In Nephropathy (REIN) study found that ACE in-
hibitors, by reducing urinary proteins, may contribute to im-
prove the outcome of nondiabetic renal disease, and reduce
the risk of progression to ESRD by about 50%. Cumulative
meta-analyses, including the REIN study results, confirmed and
extended these findings. Thus, well-designed trials in properly
selected and carefully monitored study populations continue
to be the best approach to test the efficacy of novel treatments.
The meta-analyses may help confirming the consistency of these
findings and their generalizability to larger cohorts of patients.
The number of new patients with end-stage renal dis-
ease (ESRD) entering kidney replacement programs has
progressively increased at an average of 7% per year
over the past 10 years [1]. About 1.1 million patients are
currently on renal replacement therapy worldwide. This
number will exceed two million over the next 10 years;
450,000 of them will be from the United States [2]. Even
more people will die of terminal renal failure in coun-
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tries where renal replacement therapy is not available
for the large majority of patients in need. Costs for re-
nal replacement therapy will exceed $1 trillion by 2005.
These costs will also exceed the available resources in the
richest Western countries [3, 4]. About two thirds of pa-
tients on renal replacement therapy irreversibly lose their
kidney function because of progressive nephropathies,
such as diabetic nephropathy and nondiabetic chronic re-
nal disease. Halting the progression of these patients to
ESRD is instrumental in order to substantially decrease
the need and cost for renal replacement therapy. Here
we will briefly discuss the role of proteinuria in the pro-
gression of chronic nephropathies, and of antiproteinuric
treatments in preventing progression to ESRD, with a
particular focus on the role of ACE inhibition therapy in
nondiabetic chronic nephropathies.
MECHANISMS OF RENAL DISEASE
PROGRESSION: THE ROLE OF PROTEINURIA
Experimental evidence
A large number of experimental studies have demon-
strated that chronic nephropathies share common
pathogenic mechanisms that contribute to renal disease
progression, even independently of the original etiology.
Actually, a variety of insults may result in a common path-
way of systemic hypertension, increased glomerular pres-
sure and protein ultrafiltration, glomerular and tubular
protein overload, chronic inflammation and, ultimately,
scarring [5–8].
Glomerular hypertension in both diabetic and non-
diabetic chronic nephropathies leads to increased
glomerular permeability and excessive protein filtration.
Ultrafiltered proteins are partly lost in urine (protein-
uria), and partly absorbed by endocytosis in the proximal
tubules. During periods of heavy proteinuria, the ultrafil-
tered proteins accumulate in lysosomes in the proximal
tubular cells, causing cell disruption and injury (reviewed
in [9–12]). Recent data suggest that protein overload may
also directly contribute to podocyte injury and eventual
glomerulosclerosis [13].
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Clinical evidence
A large series of observational studies and clinical tri-
als found a significant correlation between the extent of
urinary protein excretion and the rate of GFR decline, as
well as of progression to ESRD both in diabetic [14] and
nondiabetic [15] chronic nephropathies. A 20-year obser-
vational study in a large Caucasian population found that
dipstick-positive proteinuria independently predicts risk
of ESRD and overall mortality [16]. On the same line,
increased urinary albumin excretion predicted increased
renal and cardiovascular mortality eight years later in a
remote Australian Aborigine community [17]. Recently,
a population screening of almost 100,000 people in Japan
found that the risk of progression to ESRD over seven-
year follow-up was almost entirely restricted to subjects
with dipstick proteinuria at study entry, regardless of their
renal function to start with [18].
Compelling evidence of a pathogenetic role of protein-
uria in the progression of chronic renal disease derives
also by data that whenever proteinuria is reduced, re-
gardless of the adopted treatments and of the concomi-




CLINICAL TRIALS AND META-ANALYSES
Randomized, controlled trials have been used for clin-
ical research for more than two centuries, and provide
the most unbiased evidence for estimating the efficacy
of therapeutic and preventive interventions in human
subjects. However, in some circumstances, practical lim-
itations in patient recruitment and study duration may
limit the power of the analyses, in particular, when spe-
cific subgroups or possible interaction between treatment
effects and patient characteristics are considered. The
meta-analytic techniques were introduced in 1976 as a
quantitative attempt to combine the results of different
studies in order to increase the power of the analyses,
in particular, when there are several trials addressing
a similar clinical issue. Cumulative meta-analyses can
be repeated after new trial results are reported, and/or
before additional trials are undertaken. On the other
hand, heterogeneity in study populations, experimen-
tal designs, study treatments, and follow-up period of
a considered trial may limit the efficacy of these anal-
yses. An additional, potential bias is also related to the
risk of over-representation of positive, published trials
versus negative, unpublished studies. Despite these sev-
eral limitations, the meta-analytic approach has progres-
sively gained popularity over the last years, and nephrol-
ogists have started to see in this novel methodology a
powerful tool to address some of the issues not defi-
nitely addressed by clinical trials. Actually, the role of
ACE inhibitor therapy in nondiabetic renal disease has
likely been the hottest and controversial issue in clini-
cal nephrology over the last two decades. Here we will
briefly consider the specific contribution of clinical trials
and meta-analyses of clinical trials in optimizing treat-
ment and prevention of chronic nephropathies, with par-
ticular focus on the role of ACE inhibition therapy in
nondiabetic renal disease.
ACE inhibition trials in nondiabetic renal disease
Before 1995, several small published [19–22] and un-
published (Brenner BM, personal communication; Toto
R, personal communication) randomized trials evaluated
the effects of ACE inhibitors in patients with nondiabetic
renal disease. None of these, however, clearly demon-
strated a specific renoprotective effect of ACE inhibitor
therapy. Some studies found that ACE inhibitors slowed
GFR decline, but did not reduce the renal events [20],
others found some effect on events, but not on GFR
[21], and others found no effect at all [19]. Conceivably,
these studies were too small and underpowered to test
the working hypothesis. This limitation, however, did not
apply to the Angiotensin-converting-enzyme Inhibition
in Progressive Renal Insufficiency (AIPRI) study [23],
the largest trial of ACE inhibition in nondiabetic renal
disease ever performed. This study, which included 563
patients followed for an average of 3.5 years, found a
slower increase in serum creatinine on ACE inhibition
therapy than on placebo that did not translate into a re-
duced risk of progression to ESRD, however. Moreover,
the results were flawed by a much more effective blood
pressure reduction in the ACE inhibitor group that did
not allow establishing whether the beneficial effect on
serum creatinine was due to ACE inhibition, per se, or
just to a better control of arterial hypertension.
The meta-analyses of ACE inhibition trials
Since 1995 to 1997, three meta-analyses have addressed
the issue of ACE inhibition in chronic renal disease [24,
26]. The first two studies [24, 25], however, included a
heterogeneous cocktail of patients with diabetic or non-
diabetic renal disease, in which the nondiabetic popu-
lation represented only a minority of the study sample.
This likely reflected the fact than most of the studies per-
formed in the early 1990s included patients with diabetic
nephropathy, in particular, type 1. Thus, the analyses were
primarily aimed to evaluate the effects of ACE inhibitors
in chronic nephropathies regardless of the underlying
etiology. Due to the limited power, subgroup analyses
in nondiabetic patients could just evaluate whether the
trends observed in these patients reflected those more
consistently demonstrated in diabetics. Altogether, these
studies found a 40% risk reduction for ESRD or doubling
serum creatinine on ACE inhibitor therapy compared to
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Fig. 1. Risk ratios (and 95% confident intervals) of ESRD or death in a meta-analysis of 11 trials of 1594 patients with nondiabetic renal disease
randomized to ACE inhibitor therapy or placebo. Modified from [26].
placebo in both diabetic and nondiabetic patients [24,
25]. In 1997, however, the availability of a large amount of
data derived by the AIPRI trial provided for the first time
enough power to perform a meta-analysis specifically fo-
cused on chronic nondiabetic nephropathies [26]. The re-
sults, however, were discouraging. Although the study
found a marginal benefit on the risk of ESRD (Fig. 1),
the hypothesis of a specific renoprotective effect of ACE
inhibitors remained unproven because of the significantly
better blood pressure control in subjects on ACE in-
hibitor therapy. Moreover, the overall mortality was not
improved by ACE inhibition, largely because the excess
mortality observed on benazepril treatment in the AIPRI
study [23] counterbalanced the trend to a lower mortal-
ity on ACE inhibition therapy observed in the other trials
(Fig. 1). Why renal outcome data differed from those in
diabetic renal disease is unclear. A possible explanation
is that the large majority of patients considered in this
meta-analysis had mild or no proteinuria. In these cases,
the GFR decline is slow, and the renal events (ESRD
disease or doubling serum creatinine) are relatively few.
This unavoidably decreases the power of both slope-
based and event-based analyses. Another important
point is that ACE inhibitors are maximally effective in
patients with most severe proteinuria, but have only
marginal effects in those with subclinical or no protein-
uria, such as those with adult polycystic kidney disease,
or chronic tubulointerstitial nephropathies. Thus, the
results were substantially inconclusive because the meta-
analysis could not prove, or reject, the working hypothe-
sis. A different approach was needed.
The REIN study
To increase the power of the analyses, the investigators
of the Ramipril Efficacy In Nephropathy (REIN) study
decided to test the renoprotective effect of ACE inhi-
bition therapy in a population of patients predicted to
rapidly progress because of a persistently (for six months
or more) increased (1 g per day or more) urinary protein
excretion rate [27]. Serial measurements of the GFR by
the iohexol plasma clearance technique [28] allowed also
for powerful slope-based analyses of GFR decline. After
stratification for baseline proteinuria 1 to 3 g/day (Stra-
tum 1) or ≥3 g/day (Stratum 2), patients were randomized
to ramipril or placebo plus other non-renin-angiotensin-
system–inhibiting agents targeted at achieving and main-
taining a diastolic blood pressure of 90 mm Hg or less in
both treatment groups. This prevented the confounding
effect of more blood pressure reduction in the ACE in-
hibition arm that flawed the analyses of previous studies
[23]. The interim analyses of the study found a two- to
three-fold faster GFR decline in patients with baseline
proteinuria >3 g/24 hours than in those with less protein-
uria, a finding that confirmed and extended the evidence
of a specific pathogenetic role of proteinuria in the pro-
gression of chronic nephropathies [27, 29, 30] (Fig. 2).
Moreover, in patients with proteinuria >3 g/day, ramipril
halved the rate of GFR decline (Fig. 2), an effect that in-
duced the Ethical Committee to prematurely stop Stra-
tum 2 for efficacy reasons and to put all patients on
ramipril therapy regardless of the original randomiza-
tion. These patients entered the REIN follow-up study
[29]. In the meantime, final analyses of Stratum 2 (Core
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Fig. 2. Rate of GFR decline at interim anal-
ysis of 177 patients with nondiabetic chronic
nephropathies included in the REIN study, ac-
cording to baseline proteinuria and treatment
randomization.
Study) found also a halved risk of doubling serum crea-
tinine or ESRD on ACE inhibition compared to placebo
[27]. A similar benefit on renal events was subsequently
described also in Stratum 1 patients [30]. Finding that
in patients on ramipril therapy the improved outcome
was associated with more proteinuria reduction, but com-
parable blood pressure versus controls reinforced the
concept that the renoprotection conferred by ACE in-
hibition was largely mediated by the effects on urinary
proteins [27]. This was also consistent with finding that at
multivariate analyses ACEi-induced reduction in urinary
proteins was the strongest time-dependent covariate that
predicted a lower rate of GFR decline and a slower pro-
gression to ESRD. Finding that the rate of GFR decline
was correlated negatively with proteinuria reduction, and
positively with residual proteinuria, provided further ev-
idence of the role of protein traffic in the progression
of the disease [31]. Of interest, proteinuria reduction was
more consistent in patients with more proteinuria to start
with. Thus, patients with more severe disease were also
those who gained the most from ACE inhibition therapy
both in terms of more proteinuria reduction and of slower
progression.
After about 36 months of treatment with ramipril, no
further patients progressed to the point of requiring dialy-
sis, whereas patients switched from conventional therapy
to ramipril continued to develop end-stage renal disease
[32]. During the Core Study, ramipril therapy was associ-
ated with a 50% reduction in the risk of outcome events
(ESRD or doubling of serum creatinine), whereas during
the follow-up phase, patients originally randomized to
ramipril had, at most, a three-fold reduction in the
risk of reaching end points. Thus, the renoprotective
effect of ACE inhibition was clearly time-dependent,
and in the long-term resulted in a stabilization of the
disease, This remarkable outcome should be consid-
ered in the light of the fact that these patients all had
>3 g/day of proteinuria before the study and were,
therefore, expected to develop rapid decline in GFR
[33].
Of interest, post-hoc analyses found a comparable out-
come in males and females that challenged previous evi-
dence of a gender effect resulting in a fasting progression
of chronic nephropathies in males. Actually, the REIN
study found that the comparable outcomes in the two gen-
ders were the result of a faster progression on placebo,
and of a better response to ACE inhibitor therapy of fe-
males compared to males. These opposite trends were
specifically related to gender, since they persisted even
after adjustments for a series of potential confounders,
such as blood pressure control and dietary sodium and
protein intakes [34].
The cumulative meta-analyses including the REIN
study results
The Angiotensin-converting-enzyme Inhibition and
Progression of Renal Disease (AIPRD) study, a cumu-
lative meta-analysis of 11 trials including the REIN trail,
confirmed that proteinuria is a strong risk factor for pro-
gression of chronic renal disease that can be effectively
modified by ACE inhibitor therapy [35]. Of interest, the
REIN study [27] and the AIPRD meta-analysis [36] con-
sistently found that the risk reduction for ESRD achieved
by ACE inhibitor therapy versus placebo increased for in-
creasing levels of baseline proteinuria (Fig. 3). In other
words, the meta-analysis confirmed previous evidence
from the REIN study that patients with more severe re-
nal disease are those who benefit the most from ACE
inhibitor therapy. These findings were confirmed and
further extended by a pooled analysis of 2387 patients
with nondiabetic renal disease showing a strong relation-
ship between early changes in urinary proteins achieved
by different renoprotective treatments (ACE inhibition,
blood pressure reduction, or low protein diet) and subse-
quent disease outcome [33] (Fig. 4). Indeed, in the 1710
patients in whom proteinuria was reduced by treatment,
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Fig. 3. Relative risks of ESRD on ACE in-
hibition therapy or placebo according to dif-
ferent levels of baseline proteinuria in pa-
tients with nondiabetic chronic nephropathies
enrolled in the REIN Stratum 2 study (left
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Fig. 4. Renal outcomes according to changes
in urinary proteins in a pooled analysis
of 2387 patients with nondiabetic chronic
nephropathies included in 11 randomized tri-
als of different renoprotective treatments.
Modified from [33].
the outcome was also significantly improved, whereas in
the 638 patients in whom proteinuria was not reduced,
the outcome was not appreciably affected. Even more im-
portant, in no case was there a worsening in proteinuria
that was subsequently associated with an improved out-
come. Thus, in 98% of the patients, changes in proteinuria
and outcome were consistent with a pathogenetic role of
proteinuria in disease progression, and with a nephro-
protective effect of proteinuria reduction (Fig. 4). In only
39 patients was no improvement in disease outcome de-
tected, despite a reduction in urinary proteins. These
patients, however, were included into two small studies
with only one-year follow-up that were too underpow-
ered to detect any appreciable treatment effect on disease
outcome.
An additional cumulative meta-analysis of 1860 non-
diabetic patients found that in those with a basal urine
protein excretion more than 2.0 g/day, systolic blood pres-
sure of 110 to 129 mm Hg was associated with the lowest
risk for kidney disease progression [37]. In those with less
proteinuria, no relationship was found between achieved
blood pressure control and outcome. Again, these find-
ings confirmed and extended evidence from previous tri-
als, such as MDRD [38], REIN [27], and AASK [39]
studies, that the benefit of blood pressure reduction on
disease outcome strongly depends on the extent of pro-
teinuria, the outcome being substantially improved in pa-
tients with more proteinuria, but only marginally affected
in those with subclinical or no proteinuria. A novel find-
ing of this meta-analysis, however, was that systolic blood
pressures less than 110 mm Hg were associated with an
increased risk of doubling of serum creatinine or ESRD
[37], a phenomenon that to some extent recalled the “J
effect” on cardiovascular events attributed in some stud-
ies to a too intensive blood pressure reduction. A reduced
kidney perfusion was suggested to explain the worsening
renal function in patients with more blood pressure re-
duction. The authors, however, acknowledged that their
analyses could not exclude the possibility of a reverse
causation. In other words, the meta-analysis could not
establish whether the findings reflected a specific patho-
genetic role for too low blood pressure, per se, or merely
the common association between low blood pressure and
diseases such as focal segmental glomerulosclerosis and
some cases of idiopathic membranous nephropathy that
are characterized by heavy proteinuria and poor out-
come. Thus, whether intensified blood pressure control is
protective or detrimental for the kidney can be assessed
only by an ad hoc clinical trial.
A meta-analysis from the same group [40] also found
that, after adjusting for potential confounders such as
diet, blood pressure, or lipid profile, renal disease pro-
gression was comparable in women and men. These
findings challenged previous evidence of a gender
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effect on disease progression from studies that, however,
did not consider these confounders [41], and confirmed
and extended evidence from the REIN study that pro-
gression of nondiabetic renal disease was comparable
in women and men [34]. The possibility of an interac-
tion between ACEi therapy and gender arisen by the
REIN data, however, was not formally explored in this
meta-analysis.
CONCLUSION
Experimental and clinical data converge to indicate
that in chronic renal disease increased protein traf-
fic is nephrotoxic, proteinuria predicts disease progres-
sion, and proteinuria reduction is renoprotective. Initial
clinical trials failed to demonstrate that ACE inhibi-
tion therapy is renoprotective in nondiabetic chronic
nephropathies. Consistently, meta-analyses based on data
generated by these trials failed to detect a specific, blood
pressure–independent, renoprotective effect of ACE in-
hibition therapy. The REIN study found that ACE in-
hibitors, by reducing urinary proteins, may contribute to
improve the outcome of nondiabetic renal disease. Cu-
mulative meta-analyses including the REIN study results
confirmed and extended these findings.
Thus, well-designed trials in properly selected and care-
fully monitored study populations continue to be the best
approach to test the efficacy of novel treatments. The
meta-analyses may help confirming the consistency of
these findings and their generalizability to larger cohorts
of patients.
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